anti-Thyroid Drugs

PreclinicalSmall molecule

SShandong Provincial Hospital

anti-Thyroid Drugs is one of 4 small molecule programs targeting Hyperthyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperthyroidismActive, not recruiting

HyperthyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Hyperthyroidism

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Approved

1 2

Carnitor

LLeadiant Biosciences, Inc.

Approved

—3

Thiamine

UUniversiti Kebangsaan Malaysia Medical Centre

Preclinical

1 4

anti-Thyroid Drugs

SShandong Provincial Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ANot yet recruiting

Hyperthyroidism

NCT06540469

Clinical

Trials by Indication[1]

Hyperthyroidism1 trial

Iodine Supplementation in Graves' Hyperthyroidism

Not yet recruiting·SShandong Provincial Hospital·N/A·NCT06540469·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for anti-Thyroid Drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-Thyroid Drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-Thyroid Drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Provincial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShandong Provincial Hospital

anti-Thyroid Drugs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Hyperthyroidism1 trial

References

Drug Info

Quick Facts

Related News